ERBB2 and cancer: According to Weisser et al.’s hypothesis, a biparatopic Ab designed to increase receptor crosslinking and gathering might offer the receptor-Ab complex needed to connect C1q and activate the effective anti-cancer mechanism, as well as preserve and/or improve all other identifiable anti-cancer MOA assigned to authorized anti-HER2 Ab therapies (216).